1. Home
  2. JFIN vs BCTXZ Comparison

JFIN vs BCTXZ Comparison

Compare JFIN & BCTXZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JFIN
  • BCTXZ
  • Stock Information
  • Founded
  • JFIN 2011
  • BCTXZ N/A
  • Country
  • JFIN China
  • BCTXZ Canada
  • Employees
  • JFIN N/A
  • BCTXZ 12
  • Industry
  • JFIN Finance: Consumer Services
  • BCTXZ
  • Sector
  • JFIN Finance
  • BCTXZ
  • Exchange
  • JFIN Nasdaq
  • BCTXZ Nasdaq
  • Market Cap
  • JFIN 969.7M
  • BCTXZ N/A
  • IPO Year
  • JFIN 2019
  • BCTXZ N/A
  • Fundamental
  • Price
  • JFIN $15.83
  • BCTXZ $1.00
  • Analyst Decision
  • JFIN
  • BCTXZ
  • Analyst Count
  • JFIN 0
  • BCTXZ 0
  • Target Price
  • JFIN N/A
  • BCTXZ N/A
  • AVG Volume (30 Days)
  • JFIN 244.9K
  • BCTXZ N/A
  • Earning Date
  • JFIN 06-04-2025
  • BCTXZ N/A
  • Dividend Yield
  • JFIN 3.13%
  • BCTXZ N/A
  • EPS Growth
  • JFIN 2.88
  • BCTXZ N/A
  • EPS
  • JFIN 3.43
  • BCTXZ N/A
  • Revenue
  • JFIN $840,800,386.00
  • BCTXZ N/A
  • Revenue This Year
  • JFIN N/A
  • BCTXZ N/A
  • Revenue Next Year
  • JFIN N/A
  • BCTXZ N/A
  • P/E Ratio
  • JFIN $4.62
  • BCTXZ N/A
  • Revenue Growth
  • JFIN 4.83
  • BCTXZ N/A
  • 52 Week Low
  • JFIN $4.00
  • BCTXZ N/A
  • 52 Week High
  • JFIN $19.23
  • BCTXZ N/A
  • Technical
  • Relative Strength Index (RSI)
  • JFIN 51.87
  • BCTXZ N/A
  • Support Level
  • JFIN $17.25
  • BCTXZ N/A
  • Resistance Level
  • JFIN $19.23
  • BCTXZ N/A
  • Average True Range (ATR)
  • JFIN 1.29
  • BCTXZ 0.00
  • MACD
  • JFIN -0.18
  • BCTXZ 0.00
  • Stochastic Oscillator
  • JFIN 34.99
  • BCTXZ 0.00

About JFIN Jiayin Group Inc.

Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.

About BCTXZ BriaCell Therapeutics Corp. Warrant

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Share on Social Networks: